NUVB Nuvation Corp Earnings per share for the last twelve months

NUVB (Nuvation Bio Inc) - company brandmark

The absence of regular cash inflows due to the testing stage makes Nuvation Bio Inc. (NUVB) dependent on its existing capital. The change in the rolling annual EPS on GURU.Markets reflects the current trend, where -0.39 is recorded as the baseline value. This occurs amid an expansion into targeted oncology following the deal with AnHeart and high market demand for solid tumor treatments.

NUVB (Nuvation Bio Inc.) Net earnings per share for the last 12 months history from 07/04/2022 to 11/16/2026

Nuvation Corp - analytical breakdowns and key metrics (NUVB)

- current quotes and average value forecast:
Basic company analysis:nuvationbio.com (NUVB)
Mass-produced product of Nuvation Pharma

This indicator measures the equity value of the business via net income per share on a trailing twelve-month (TTM) basis, reflecting the issuer's actual financial return. By analyzing the change in TTM net income per share, an investor can see the impact of oncology drug development costs for Nuvation Bio Inc. (NUVB), where current negative values are justified by investments in intellectual property for future monetization.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Day One (DAWN) - Earnings per share for the last twelve months|Earnings per share for the last 12 months MNPR|INBX (inhibrx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months i-mabbiopharma.com (IMAB)|Earnings per share for the last twelve months Fennec (FENC)|HRTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Nuvectis NVCT|Coherus Biosciences - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months cardiffoncology.com|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months